China Plays Crucial Role in Insilico’s Ambitious Quest to Create an AI ‘Einstein’ for Drug Discovery

Insilico Medicine, founded by Alex Zhavoronkov, likens biotechnology to a “molecular casino,” highlighting the high risks involved in drug discovery, where success rates can be as low as 10%. The company has developed Pharma.AI, an AI-powered drug discovery tool designed to enhance speed, cost-efficiency, and success in discovering novel drugs. This innovative platform is compared to an “Einstein” that can integrate diverse fields such as biology, chemistry, and math. Over the next three to five years, Insilico plans to share some AI capabilities, allowing pharmaceutical firms to accelerate their own discoveries via a subscription model, aiming for pricing around US$20 per month. The generative AI platform can create new drug molecules from genomic data rather than relying on existing chemical libraries. Despite reporting a significant net loss of US$19.22 billion in the first half of this year, Insilico continues to generate revenue primarily through licensing drug candidates and selling AI software.

Source link